Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

• DOI: 10.1002/alz.12545
• Publication Date: 2021-12-22T12:18:10Z
• Authors: Constance Delaby; Charlotte E. Teun...; Kaj Blennow; Daniel Alcolea; Ivan Arisi; Elodie Bouaziz Amar; Anne Beaume; Aurélie Bedel; Giovanni Bellomo; Edith Bigot‐Corbel; Maria Bjerke; Marie‐Céline Blan...; Mercè Boada; Olivier Bousiges; Miles D Chapman; Mari L. DeMarco; Mara D'Onofrio; Julien Dumurgier; Diane Dufour‐Rain...; Sebastiaan Engelb...; Hermann Esselmann; Anne Fogli; Audrey Gabelle; Elisabetta Galloni; Clémentine Gondolf; Frédérique Grandh...; Oriol Grau‐Rivera; Melanie Hart; Takeshi Ikeuchi; Andreas Jeromin; Kensaku Kasuga; Ashvini Keshavan; Michael Khalil; Peter Körtvelyessy; Agnieszka Kulczyn...; Jean‐Louis Laplanche; Piotr Lewczuk; Qiao‐Xin Li; Alberto Lleó; Catherine Malaplate; Marta Marquié; Colin L. Masters; Barbara Mroczko; Léonor Nogueira; Adelina Orellana; Markus Otto; Jean‐Baptiste Oudart; Claire Paquet; Federico Paolini ...; Lucilla Parnetti; Armand Perret‐Lia...; Katell Peoc'h; Koen Poesen; Albert Puig‐Pijoan; Isabelle Quadrio; Muriel Quillard‐M...; Benoit Rucheton; Susanna Schraen; Jonathan M. Schott; Leslie M. Shaw; Marc Suárez‐Calvet; Magda Tsolaki; Hayrettin Tumani; Chinedu T Udeh‐Momoh; Lucie Vaudran; Marcel M Verbeek; Federico Verde; Lisa Vermunt; Jonathan Vogelgsang; Jens Wiltfang; Henrik Zetterberg; Sylvain Lehmann
• Keywords: [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology; Consensus approach; Clinical Neurology; 610; tau Proteins; cerebrospinal fluid [Amyloid beta-Peptides]; DIAGNOSIS; RECOMMENDATIONS; Cerebrospinal fluid biomarkers; Alzheimer Disease; 616; CRITERIA; Humans; ddc:610; cerebrospinal fluid [Peptide Fragments]; clinical report; cerebrospinal fluid biomarkers; consensus approach; Science & Technology; Amyloid beta-Peptides; Featured Articles; 9. Industry and infrastructure; diagnosis [Alzheimer Disease]; Radboudumc 3: Disorders of movement DCMN: Donders Center for Medical Neuroscience; Alzheimer's disease; 16. Peace & justice; Clinical report; Peptide Fragments; 3. Good health; cerebrospinal fluid [Alzheimer Disease]; Alzheimer's disease; cerebrospinal fluid biomarkers; clinical report; consensus approach; harmonization; cerebrospinal fluid [Biomarkers]; cerebrospinal fluid [tau Proteins]; Harmonization; harmonization; Neurosciences & Neurology; Human medicine; Life Sciences & Biomedicine; Alzheimer’s disease; Biomarkers

Abstract Introduction The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting results may differ, which can lead misunderstandings raises questions about commutability tests. Methods We obtained description (pre‐)analytical protocols sample reports 40 centers worldwide. A consensus approach allowed us propose harmonized comments corresponding different CSF biomarker profiles observed patients. Results procedures were similar between centers. There was considerable heterogeneity cutoff definitions report comments. therefore identified selected by most accurate informative regarding context AD diagnosis. Discussion This is first time that are proposed across worldwide specialized laboratories involved AD.